NeoGenomics, Inc. (NASDAQ:NEO) is Kopp Family Office LLC’s 4th Largest Position

Kopp Family Office LLC trimmed its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 1.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 926,975 shares of the medical research company’s stock after selling 17,800 shares during the quarter. NeoGenomics comprises about 8.8% of Kopp Family Office LLC’s investment portfolio, making the stock its 4th largest position. Kopp Family Office LLC’s holdings in NeoGenomics were worth $13,673,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of NEO. Loomis Sayles & Co. L P bought a new stake in shares of NeoGenomics during the 3rd quarter valued at about $17,807,000. Segall Bryant & Hamill LLC boosted its position in NeoGenomics by 67.0% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company’s stock valued at $27,928,000 after acquiring an additional 759,524 shares in the last quarter. First Light Asset Management LLC raised its position in shares of NeoGenomics by 14.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after acquiring an additional 480,396 shares in the last quarter. Bellevue Group AG grew its stake in NeoGenomics by 34.2% in the third quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company’s stock worth $23,786,000 after purchasing an additional 410,516 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in NeoGenomics by 7.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock valued at $46,108,000 after buying an additional 217,687 shares during the period. 98.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NEO has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday, November 6th. Benchmark reaffirmed a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a research report on Tuesday, September 24th. Jefferies Financial Group started coverage on shares of NeoGenomics in a research note on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Bank of America upped their target price on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.30.

NeoGenomics Stock Performance

Shares of NASDAQ NEO traded down $0.39 during trading on Tuesday, hitting $16.53. The company had a trading volume of 103,074 shares, compared to its average volume of 798,937. The firm has a market capitalization of $2.12 billion, a P/E ratio of -27.10 and a beta of 1.24. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics, Inc. has a 12 month low of $12.77 and a 12 month high of $19.00. The stock has a 50 day simple moving average of $16.14 and a 200 day simple moving average of $15.42.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The company had revenue of $167.80 million for the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.06) earnings per share. As a group, analysts anticipate that NeoGenomics, Inc. will post -0.16 earnings per share for the current year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.